00:06:45
High-risk mechanism claim
Presents detailed receptor and biochemical explanations as a basis for optimization.
Review topic: retatrutide mechanism.
Checked against: Retatrutide phase 2 results: 24.2% weight loss (NEJM)
Video claim watch
Retatrutide Masterclass (the 'how to' for EVERYTHING) - Dr Trevor Bachmeyer
Another long-form retatrutide masterclass format that helps compare recurring claims and audience questions.
Dr Trevor Bachmeyer channel1:16:50 runtime200K views when checked
Transcript review
6 material claims logged
Published with source gaps audit stateauto-captioned transcript2 operational-guidance flags3 source gaps
Reviewed Jul 12, 2026. Next review Aug 12, 2026.
highest-risk alongside Quinn; contains detailed preparation/administration material plus sweeping disease claims.
auto-caption available; 20 creator chapters.
Claim-by-claim audit
What the video says, and what needs checking
00:12:03
High-risk evidence claimOperational guidance
Makes prescriptive diet/macronutrient claims, including categorical claims about low-carbohydrate diets causing insulin resistance and undermining retatrutide.
Review topic: diet interaction.
Checked against: Primary-source record still needed
trial protocols; no validated retatrutide-specific nutrition comparison is cited.
Handling: This segment contains operational guidance for an unapproved product. Peptide Report does not reproduce or endorse those instructions.
00:30:03
Operational guidanceHigh-risk safety claimHigh-risk regulatory claim
Provides dosing strategies and later (00:39:50) preparation/reconstitution and syringe instructions.
Review topic: investigational drug administration.
Checked against: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
Do not reproduce or operationalize.
Handling: This segment contains operational guidance for an unapproved product. Peptide Report does not reproduce or endorse those instructions.
00:42:54
High-risk evidence claimHigh-risk mechanism claim
Expands into claimed neuroprotection, cognitive benefits, neuropathic-pain benefits, and mitochondrial effects.
Review topic: retatrutide / neurology.
Checked against: Primary-source record still needed
retatrutide clinical registries; GLP-1 class or animal findings cannot be attributed to retatrutide clinical efficacy.
01:00:51
High-risk safety claim
minimizes cancer concern using class-level data and argues metabolic improvement reduces cancer risk.
Review topic: cancer risk.
Checked against: Primary-source record still needed
future retatrutide safety data plus approved GLP-1 labels; absence of observed events does not erase label/theoretical uncertainties.
01:02:35
High-risk evidence claim
makes broad claims that retatrutide corrects core failures shared by diabetes, heart disease, dementia, cancer, autoimmune disease, obesity and more.
Review topic: multi-disease efficacy.
Checked against: TRIUMPH-1: retatrutide in participants with obesity or overweight
label as unsupported extrapolation.
Source check
Records used in this claim audit
Retatrutide for Obesity: A Phase 2 Trial
Retatrutide phase 2 obesity trial (NEJM 2023): at 12 mg, mean body weight fell 17.5% at week 24 and 24.2% at week 48; GI adverse events were most common.
12 linked pagesOpen original ·
nejm-retatrutide-phase2-2023FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Accessed 2026-07-12.
11 linked pagesOpen original ·
research-reta-02TRIUMPH-1: retatrutide in participants with obesity or overweight
Completed Phase 3 master protocol NCT05929066. The registry identifies TRIUMPH-1 as a randomized, double-blind, placebo-controlled study in adults without type 2 diabetes who have obesity or overweight.
12 linked pagesOpen original ·
clinicaltrials-retatrutide-triumph1